ATORVALIQ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Atorvaliq, and when can generic versions of Atorvaliq launch?
Atorvaliq is a drug marketed by Cmp Dev Llc and is included in one NDA. There are three patents protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in ATORVALIQ is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atorvaliq
A generic version of ATORVALIQ was approved as atorvastatin calcium by SUN PHARM INDS LTD on November 30th, 2011.
Summary for ATORVALIQ
International Patents: | 2 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 31 |
Patent Applications: | 142 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ATORVALIQ |
What excipients (inactive ingredients) are in ATORVALIQ? | ATORVALIQ excipients list |
DailyMed Link: | ATORVALIQ at DailyMed |
Pharmacology for ATORVALIQ
Drug Class | HMG-CoA Reductase Inhibitor |
Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ATORVALIQ
US Patents and Regulatory Information for ATORVALIQ
ATORVALIQ is protected by four US patents.
Patents protecting ATORVALIQ
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: AS AN ADJUNCT TO DIET TO REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: AS AN ADJUNCT TO OTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LOWERING THERAPIES, OR ALONE IF SUCH TREATMENTS ARE UNAVAILABLE, TO REDUCE LDL-C IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD FOR LOWERING CHOLESTEROL LEVEL IN A HUMAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cmp Dev Llc | ATORVALIQ | atorvastatin calcium | SUSPENSION;ORAL | 213260-001 | Feb 1, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cmp Dev Llc | ATORVALIQ | atorvastatin calcium | SUSPENSION;ORAL | 213260-001 | Feb 1, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cmp Dev Llc | ATORVALIQ | atorvastatin calcium | SUSPENSION;ORAL | 213260-001 | Feb 1, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ATORVALIQ
See the table below for patents covering ATORVALIQ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 3468606 | NOUVELLE COMPOSITION PHARMACEUTIQUE DE COMPOSÉ HYPOLIPIDÉMIANT (A NOVEL PHARMACEUTICAL COMPOSITION OF A LIPID LOWERING COMPOUND) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2017212409 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ATORVALIQ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0247633 | 97C0103 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107 |
0247633 | 62/1997 | Austria | ⤷ Try a Trial | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
1003503 | SZ 30/2006 | Austria | ⤷ Try a Trial | PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN |
0247633 | C970034 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
0720599 | 300689 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |